Stroke in Women: A Review Focused on Epidemiology, Risk Factors, and Outcomes

Cindy W. Yoon; Cheryl D. Bushnell

doi:10.5853/jos.2022.03468

J Stroke > Volume 25(1); 2023 > Article

Yoon and Bushnell: Stroke in Women: A Review Focused on Epidemiology, Risk Factors, and Outcomes

Review

Journal of Stroke 2023;25(1):2-15.

Published online: January 31, 2023

DOI: https://doi.org/10.5853/jos.2022.03468

Stroke in Women: A Review Focused on Epidemiology, Risk Factors, and Outcomes

Cindy W. Yoon^a, Cheryl D. Bushnell^b

^aDepartment of Neurology, Inha University School of Medicine, Incheon, Korea

^bDepartment of Neurology, Wake Forest University School of Medicine, Winston Salem, NC, USA

Correspondence: Cheryl D. Bushnell Department of Neurology, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157, USA Tel: +1-336-716-2983 Email: cbushnel@wakehealth.edu

Received November 5, 2022 Revised December 14, 2022 Accepted January 4, 2023

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Stroke is a particularly important issue for women. Women account for over half of all persons who experienced a stroke. The lifetime risk of stroke is higher in women than in men. In addition, women have worse stroke outcomes than men. Several risk factors have a higher association with stroke in women than in men, and women-specific risk factors that men do not have should be considered. This focused review highlights recent findings in stroke epidemiology, risk factors, and outcomes in women.

Keywords: Women; Female; Sex; Stroke; Pregnancy

Introduction

Globally, stroke remained the second-leading cause of death and the third-leading cause of disability and death combined in 2019 [1]. Stroke is a particularly important issue for women, who account for over half (56% in 2019) of all persons who have experienced a stroke [2]. Women have higher lifetime risk (LTR) of stroke [3] and poorer stroke outcome [4] than men. In women, the distribution of some risk factors and the risk of stroke with those risk factors are different from men. Women also have unique risk factors that men do not have. In this review, we present a focused and updated review of stroke epidemiology, risk factors, and outcomes in women.

Epidemiology

Incidence of stroke

A lower age-adjusted incidence of stroke in women than in men has been consistently reported [5-7]. It has been generally accepted that the stroke incidence is much lower in women than in men until well after menopause in older women [5]. However, inconsistent with this previous knowledge, recent studies have reported that women have a higher or similar stroke incidence as compared to men in younger age strata (Table 1) [6-9]. After that, in middle age, men show a higher stroke incidence than women [5-8]. The difference in stroke incidence between men and women narrows as the stroke incidence increases in postmenopausal women, and eventually, the stroke incidence in women is close to [5-8] or even higher [10] than men in the eighth decade. Particularly in older women, significant disparities by race/ethnicity were reported in NOMAS (Northern Manhattan Study) [11]. For example, Black and Hispanic women aged ≥70 years had a 76%-77% higher risk of stroke compared with White women after adjustment for age, education, and insurance status, while no differences were observed in men [11].

Globally, the age-standardized incidence rate of stroke decreased between 1990 and 2019 by 17% [1]; although there are regional variations across countries and greater burdens in low- and middle-income countries than in high-income countries [1,12]. In the GCNKSS (Greater Cincinnati/Northern Kentucky Stroke Study) with a large population representative of the United States (US), the overall stroke incidence between 1993/1994 and 2015 declined significantly for both sexes: the declines were from 229 to 174 (per 100,000) for women and from 282 to 211 (per 100,000) for men [6]. The ARIC (Atherosclerosis Risk in Communities) study reported that the stroke incidence rates in adults ≥65 years decreased by 32% per 10 years during the 30-year period from 1987 to 2017, and the decreases were similar between men and women [13].

Lifetime risk of stroke

It is generally considered that the LTR of stroke is higher in women than in men, mainly due to their longer life expectancy. According to the estimation from the Framingham Study, the LTR in middle-aged adults is approximately 1 in 5 (20%-21%) for women and 1 in 6 (14%-17%) for men [3]. In the Global Burden of Disease (GBD) study, the global LTR of stroke from the age of 25 years onward was 25.1% for women and 24.7% for men in 2016 [14], but there were geographic variations with the highest LTRs among women in Eastern Europe (36.5%) and East Asia (36.3%) [14].

Stroke subtype

Contrary to other stroke subtypes, subarachnoid hemorrhage (SAH) tends to be more common in women than in men [7]. In a recent study from Canada, women had a higher hazard of SAH compared to men (hazard ratio [HR] [95% confidence interval (CI)], 1.29 [1.24-1.33]), whereas had a lower hazard of ischemic stroke (0.78 [0.77-0.79]), transient ischemic attack (TIA) (0.85 [0.84-0.86]), and intracerebral hemorrhage (ICH) (0.76 [0.74-0.78]) [7]. Intracranial aneurysm is more prevalent in women than men [15,16]. Female sex has also been reported as a risk factor for de novo aneurysm formation and growth of aneurysms [16]. In a recent meta-analysis, female sex was associated with greater odds of aneurysmal SAH (HR [95% CI], 1.90 [1.47-2.46]) [17]. Decreased estrogen levels after menopause have been suspected to affect the increased risk of aneurysm formation and rupture in women [16].

Risk factors (Figure 1)

Common risk factors

Hypertension

Hypertension (HTN) is the most prevalent risk factor for stroke. In 2019, the global age-standardized prevalence of HTN (defined as having systolic/diastolic blood pressure [SBP/DBP] ≥140/90 mm Hg or taking medication for HTN) was 34% for men and 32% for women [18]. Although the overall prevalence of HTN is higher in men than in women [18,19], the prevalence according to age shows a different trend [19]. As age increases, the prevalence of HTN increases in both men and women; however, the prevalence of HTN in postmenopausal women rises steeply, with the prevalence in women eventually exceeding that in men [19]. Similarly, the association between age and SBP in men and women who were not receiving antihypertensive treatment showed a linear increase, with the mean blood pressure (BP) in women exceeding that in men at 75 years of age in the May Measurement Month (MMM) 2018 report [20].

Regarding the awareness, treatment, and control rates of HTN, there have been many reports that these are higher in women than in men [18,19,21-25]. Globally, the treatment rate was 47% in women and 38% in men, and BP was controlled in less than half of those who received treatment, leading to global control rates of 23% for women and 18% for men with HTN [18]. However, since the awareness, treatment, and control rates are affected by various factors other than sex such as age and regional factors including health care system, race/ethnicity, and socioeconomic and cultural differences, these factors should be considered together [18-26]. For example, the overall sex difference in the control rate of HTN (women > men) is mainly due to the difference at younger ages (defined variously by studies from <40 to <60 years of age), and this sex gap diminishes with increasing age [22-25]. In reports from US and South Korea, the control rates were even reversed (men > women) from the age group ≥60 years [22,25].

HTN is the risk factor that has the greatest influence on the risk of stroke in both men and women. The INTERSTROKE (Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries) study suggested that 10 common risk factors could explain approximately 90% of the population attributable risk (PAR) for stroke [27]. Among the 10 risk factors, HTN was the factor contributing the most, and the PAR in women and men was 52.3% and 45.2%, respectively [27]. Regarding sex differences in the effect of HTN on stroke risk, previous and recent studies have shown different results. A previous meta-analysis demonstrated a similar impact of BP on the risk of stroke in both sexes; for every 10 mm Hg increase in SBP, stroke risk increased by ≈25% [28]. However, in a recent large population-based cohort study from the UK, HTN was associated with a greater HR of stroke in women than men with a women-to-men ratio of HR of 1.36 (95% CI, 1.26-1.47) [29]. The REGARDS (Reasons for Geographic and Racial Differences in Stroke) study from the US found that the association between the increase in HTN severity and incident ischemic stroke was almost twice as great in women as in men [30]. A recent large community-based cohort study (n=27,542, 54% women) suggested that the risk of stroke begins at lower thresholds of SBP for women than for men [31]. In this study, the stroke risk for women with an SBP of 120-129 mm Hg was comparable to the risk in men with an SBP of 140-149 mm Hg.

Diabetes mellitus

The global prevalence of diabetes mellitus (DM) in 2019 was estimated to be 9.3% (adults aged 20-79 years) and was reported to be slightly higher in men (9.6%) than in women (9.0%) [32]. Regarding the treatment and control rates of DM, the results have not been consistent between studies. According to the data from the US National Health and Nutrition Examination Survey, the treatment and control rates were similar or higher in women than men (81% and 30%, respectively, for women and 80% and 20%, respectively, for men in 2013-2016) [33]. In contrast to the trend in this study, in another study from Italy, the rate of achievement of target hemoglobin A1C (<7%) was lower in women (33.8%) than in men (40.2%) [34].

DM is an important risk factor for stroke with HRs (95% CI) of 2.27 (1.95-2.65) for ischemic stroke and 1.56 (1.19-2.05) for hemorrhagic stroke according to a meta-analysis from 2010 [35]. Among the ischemic stroke subtypes, DM is particularly closely related to the risk of lacunar stroke [36]. The effect of DM on stroke risk is greater than in women than in men. In a pooled analysis of 64 cohorts, women with DM had a 27% greater relative risk (RR) of stroke than men with DM [37]. In the UK Biobank cohort study, DM was associated with a higher HR of ischemic stroke in women than men with a women-to-men ratio of HR of 1.25 (95% CI, 1.00-1.56) [29]. DM was also associated with a higher RR of death after ischemic stroke in women compared to men (RR [95% CI], 3.16 [2.44-4.10] vs. 2.20 [1.75-2.77]) in a previous meta-analysis [38].

Atrial fibrillation

Women have lower age-adjusted incidence and prevalence of atrial fibrillation (AF) than men [39]. However, because of the longer life expectancy for women, the LTR of AF for women and the absolute number of women with AF are similar to those of men [39]. Female sex is considered as a risk factor for AF-related systemic thromboembolism including stroke; for this reason, female sex itself is included as a variable in AF risk stratification models such as the CHA₂DS₂-VASc score [39]. In a meta-analysis of 30 cohort studies, AF was associated with a nearly two-fold higher risk of stroke in women than in men with a women-to-men ratio of RR of 1.99 (95% CI, 1.46-2.71) [40]. In the UK Biobank cohort study, AF was also associated with a higher HR of hemorrhagic stroke in women than in men with a women-to-men ratio of HRs of 2.80 (95% CI, 1.07-7.36) [29]. There is also the view that female sex is a risk modifier rather than a risk factor for stroke in AF [41].

Despite the higher AF-related thromboembolism risk, women with AF show lower oral anticoagulation (OAC) use than men. In an analysis of the PINNACLE (Practice Innovation and Clinical Excellence) registry (n=691,906, 48.5% women), women were significantly less likely to receive OAC overall (56.7% vs. 61.3%; P<0.001) and at all levels of CHA₂DS₂-VASc score [42]. More recent study has also shown consistent results, and lower OAC use may partially mediate the increased risk of stroke in women [43]. Women are also less likely to undergo catheter ablation of AF [44]. Furthermore, women who underwent catheter ablation of AF experience lower efficacy and a higher risk of stroke/TIA and major complications than men [45]. Recent studies have also shown that women are more likely to experience worse periprocedural outcomes after left atrial appendage closure [46,47].

Dyslipidemia

The prevalence of dyslipidemia has been generally reported to be higher in men or similar in men and women [33,48]. According to the data from the US National Health and Nutrition Examination Survey, a higher percentage of men than women with cardiovascular disease (CVD) had dyslipidemia, whereas rates were similar for those without CVD [33]. Dyslipidemia is a risk factor for ischemic stroke, especially for stroke due to large artery atherosclerosis [49-51]. In most studies, there is an association between higher total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels and increased ischemic stroke risk [50,51]. In a prospective women’s cohort study of more than 27,000 US women aged ≥45 years, when comparing the highest to the lowest quintile, the multivariable-adjusted HRs of ischemic stroke were 2.27 (95% CI, 1.43-3.60) for TC and 1.74 (95% CI, 1.14-2.66) for LDL-C [52]. Regarding sex differences in the association between dyslipidemia and stroke, there were no appreciable sex differences regarding the association between TC and ischemic stroke in a previous meta-analysis of data from 61 cohorts (n=577,642, 11,914 stroke cases) [53]. In the UK Biobank cohort study, there was also no evidence of a sex difference in the associations between lipid profiles (TC, LDL-C, and high-density lipoprotein cholesterol) and stroke [29].

Statin therapy has many benefits for ischemic stroke [54]. Statin therapy shows similar effectiveness for the prevention of major vascular events in men and women at an equivalent risk of CVD [55]. Despite the similar effectiveness of statin therapy in men and women, women are less likely than men to be treated with statins in real practice [56,57]. In the PALM (The Patient and Provider Assessment of Lipid Management) registry, a US nationwide registry of outpatients with or at risk for atherosclerotic CVD, women were less likely than men to be prescribed any statin therapy (67.0% vs. 78.4%; P<0.001) or to receive a statin at the guideline-recommended intensity (36.7% vs. 45.2%; P<0.001) [57].

Migraine

Migraine is more prevalent in women than in men. According to the GBD study, for 2016, the global age-standardized prevalence of migraine was 14.4% overall: 18.9% for women vs. 9.8% for men [58]. Migraine, particularly migraine with aura, is associated with an increased risk of stroke. The possible mechanisms explaining the migraine-stroke connection include genetic predisposition, endothelial dysfunction, coagulation abnormalities, arterial dissection, and paradoxical embolism via a patent foramen ovale (PFO) [59]. In a meta-analysis of 16 cohort studies, migraine with aura was associated with a higher risk of stroke with an adjusted HR of 1.56 (95% CI, 1.30-1.87); however, this finding was not evident in migraine without aura [60]. The association of ischemic stroke risk with migraine was consistently observed, but conflicting results were shown for hemorrhagic stroke: some studies have found an increased risk for hemorrhagic stroke in migraineurs [60,61], while others have found no association [62,63]. Women showed a higher association between migraine and ischemic stroke than men (RR [95% CI], 2.08 [1.13-3.84] vs. 1.37 [0.89-2.11]), and this was especially higher in young women under the age of 45 (RR [95% CI], 3.65 [2.21-6.04]) and women using oral contraceptives (RR [95% CI], 7.02 [1.51-32.68]) [63]. The association between migraine and ischemic stroke was stronger in smokers than in non-smokers (RR [95% CI], 9.03 [4.22-19.34] vs. 1.56 [0.41-5.85]) [63].

Obesity

The prevalence of obesity is greater for women than for men [64,65]. Obesity is a risk factor for ischemic stroke in both men and women [29,66]. In the UK Biobank cohort study, obesity was associated with an increased risk of total stroke of ≈30% in both sexes with a stronger association in women than men for ischemic stroke (women-to-men ratio of HR [95% CI], 1.36 [1.21-1.54]) [29]. However, for hemorrhagic stroke, only men showed a significant association in this study [29]. A UK prospective study in women found that a higher body mass index was associated with an increased risk of ischemic stroke but a decreased risk of hemorrhagic stroke in women [67].

Smoking

The prevalence of smoking is lower in women than in men [33,68]. According to the meta-analysis including 14 studies involving 303,134 subjects, smokers had an overall increased risk of stroke compared with non-smokers with an odds ratio (OR) of 1.61 (95% CI, 1.34-1.93), and there was a dose-dependent relationship between current smoking status and the risk of stroke: the risk was increased by 12% for each increment of 5 cigarettes per day [69]. A meta-analysis published in 2013 showed that smoking-related stroke risk was similar for men and women, and only Western women (not Asian women) showed a greater risk than men [70]. However, a more recent meta-analysis showed a greater smoking-related stroke risk in women than in men (OR [95% CI], 1.88 [1.45-2.44] vs. 1.54 [1.11-2.13]) [69]. In the UK Biobank cohort study, current smokers have a considerably higher risk of stroke than never smokers, with evidence to suggest that the excess risk of stroke is greater for women than men (women-to-men ratio of HR [95% CI], 1.18 [1.02-1.36]) [29].

Women-specific risk factors

Pregnancy

Maternal stroke

Pregnancy-related stroke, commonly called maternal stroke, is a term for ischemic or hemorrhagic strokes that occur during pregnancy and the postpartum period (defined variously by studies as up to 12 weeks after delivery). In a meta-analysis including 11 studies, the pooled crude incidence rate of maternal stroke was 30.0 per 100,000 pregnancies [71], which is nearly three times that of non-pregnant women of similar reproductive age. According to recent trend studies, the incidence rate of maternal stroke has unchanged [72] or even increased [73].

The risk of maternal stroke is higher in the peripartum and postpartum periods than in the antepartum period. A population-based cohort study from UK found that the risk of stroke was slightly lower in the antepartum period but 9-fold higher in the peripartum period (defined as 2 days prior to 1 day after delivery in this study) and 3-fold higher in the first 6 weeks postpartum compared to the non-pregnant period [74]. In this study, the risks of ischemic and hemorrhagic stroke were both increased during the high-risk period [74]. Similarly, a recent study showed an increased risk of cerebral venous thrombosis (CVT) during the postpartum period; this risk was the highest during the first 6 weeks postpartum (adjusted OR [95% CI], 18.7 [8.3-41.9]), but there was no significantly increased risk during the antepartum period (adjusted OR [95% CI], 1.2 [0.6-2.3]) [75].

Physiological changes during pregnancy affecting stroke occurrence (Figure 2)

Various physiological changes occur during pregnancy. The three major changes associated with stroke are as follows: changes in the (1) hemodynamic/vascular system, (2) coagulation system, and (3) immune system.

Blood volume and cardiac output usually increase by ≈45% compared with pre-pregnancy levels to meet the increased metabolic demands of the mother and fetus [76]. Cardiac output peaks during labor and immediately after delivery, with increases of 60%-80% above levels seen before the onset of labor [76]. Physiological anemia occurs because plasma volume expansion is greater than the increase in red blood cells through erythropoiesis [76]. The increase in intravascular volume and cardiac output during pregnancy may worsen the condition of patients with pre-existing heart disease, contributing to increased risk of cardioembolic events including stroke [77]. These hemodynamic changes can also lead to increased hemodynamic stress on the arterial wall, and although controversial, it may affect the enlargement and increased rupture risk of arteriovenous malformations (AVMs) and cerebral aneurysms [78,79] or the development of dissection [80]. The major vascular change during pregnancy is vasodilation of the systemic vasculature, which causes a decrease in systemic vascular resistance and promotes venous stasis [76]. Venous stasis is exacerbated by compression of the inferior vena cava by the gravid uterus and decreased physical activity during late pregnancy and puerperium.

During pregnancy and the postpartum period, a hypercoagulable state is induced with a 4- to 10-fold increased thrombotic risk [81]. The hypercoagulable state results from an increase in procoagulant activity and a decrease in physiological anticoagulants. During pregnancy, the concentrations of coagulation factors VII, VIII, X, and XII and von Willebrand factor increase significantly accompanied by a pronounced increase in fibrinogen levels [81,82]. Physiological anticoagulation is reduced by a significant reduction in protein S activity and by acquired activated protein C resistance [81]. Fibrinolytic activity is also reduced during pregnancy due to increasing levels of plasminogen activator inhibitor-1 and placenta-derived plasminogen activator inhibitor type 2 [81,82]. In women with pre-existing hematologic disease, such as antiphospholipid syndrome and sickle cell disease, the risk of thrombotic events including stroke is even higher [83].

Pregnancy is considered a period of immunomodulation with greater inflammation in early and late pregnancy and lesser inflammation in mid-pregnancy [84]. Immune cells and their byproducts including many cytokines and growth factors play an important role in the implantation and establishment of the placenta in early pregnancy and in the induction of labor and delivery in the peripartum period [85]. However, an exaggerated inflammatory response due to dysregulation of this immunomodulation may lead to endothelial dysfunction, which is known to cause preterm birth and preeclampsia [86] and may increase stroke risk [87].

Pathological conditions in pregnancy affecting stroke occurrence (Figure 2)

• Hypertensive disorders of pregnancy: Hypertensive disorders of pregnancy (HDPs) are common medical complications of pregnancy. HTN in pregnancy can be chronic (predating pregnancy or diagnosed before 20 weeks of pregnancy) or de novo (either preeclampsia or gestational HTN) [88]. HDPs are classically classified into four types (each prevalence %) as follows: (1) preeclampsia (5%-7%), (2) gestational HTN (6%-7%), (3) chronic HTN (1%-5%), and (4) chronic HTN with superimposed preeclampsia (0.2%-1%) [89]. In a US nationwide cross-sectional study, women with HDPs were 5.2 times more likely to have a maternal stroke than those without [90]. HDPs are related not only to maternal stroke but also to future stroke [91]. The pathogenesis of HDPs remains unclear. One of the proposed mechanisms of preeclampsia is that reduced placental perfusion due to failed remodeling of the maternal vessels supplying the intervillous space leads to oxidative stress [92,93]. Then, oxidative stress stimulates activation of an excessive systemic inflammatory response, which causes endothelial dysfunction and vasoconstriction, leading to systemic HTN and end-organ hypoperfusion [92,93]. Endothelial dysfunction, blood-brain barrier disruption, and impaired cerebral autoregulation may play a central role in the cerebrovascular complications seen in preeclampsia [94].

• Peripartum cardiomyopathy: Peripartum cardiomyopathy (PPCM) is characterized by left ventricular (LV) systolic dysfunction and symptoms of heart failure (HF) that occur between the late stages of pregnancy and the early postpartum period without other cause of LV dysfunction. In a meta-analysis, patients with PPCM had a much higher prevalence of preeclampsia (22%) more than four times the average global rate expected in the general population (5%) [95]. In addition to preeclampsia, multiple gestations and multiparity are risk factors for the development of PPCM [95]. The pathogenesis of PPCM is poorly understood but may be related to a genetic predisposition and the toxic roles of profound pregnancy hormonal fluctuations during the third trimester and at birth that result in a disrupted maternal cardiovascular and metabolic homeostasis [96].

The majority of PPCM cases occur in the postpartum period, and most women present with signs and symptoms of HF [97]. In a multinational registry including over 700 women with PPCM from 49 countries, symptom-onset occurred most often within one month of delivery (44%), and 67% had an LV ejection fraction ≤35% at diagnosis [98]. The incidence of thromboembolic events was 7%, and stroke occurred in 3% by six months. The six-month mortality rate was 6%, and myocardial recovery occurred only in 46% [98].

Etiology of maternal stroke (Figure 2)

Hemorrhagic strokes account for almost 60% of strokes in pregnancy and the postpartum period, which is much higher than the rate in the general population [99]. Uncontrolled HTN and coagulopathy such as disseminated intravascular coagulation or HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome can cause hemorrhagic maternal stroke. In a recent cohort study, of the women who experienced ICH during pregnancy and the postpartum period, approximately one-third (35.3%) had preeclampsia/eclampsia, and 9.2% had coagulopathy [100]. Hemorrhagic maternal stroke can occur secondary to rupture of pre-existing vascular lesions such as AVMs and cerebral aneurysms [78,79].

Various vasculopathies can cause maternal stroke. Reversible cerebral vasoconstriction syndrome (RCVS) is a common etiology of maternal stroke, and most commonly occurs postpartum [101]. RCVS causes vasospasm of the cerebral arteries and can be associated with both hemorrhagic and ischemic strokes. Cerebral arterial dissection is also an important etiology of maternal stroke. In a recent case-control study, pregnancy was associated with a higher risk of cervical artery dissection (incidence rate ratio [95% CI], 2.2 [1.3-3.5]), and this risk was particularly high during the postpartum period [80]. Hemodynamic stress on arterial wall caused by increase in intravascular volume and cardiac output, altered arterial elasticity and stiffness due to hormonal changes, and vessel wall damage induced by Valsalva maneuvers during labor are suggested as possible mechanisms of pregnancy-related dissection, but it is still uncertain [80]. Moyamoya disease is a non-inflammatory vasculopathy that can be challenging to manage in pregnancy because there is a risk of both hemorrhagic and ischemic stroke [102].

Cardioembolism is an important etiology of maternal strokes, as well. For example, pregnant women with pre-existing heart disease such as congenital heart disease could be at risk of cardioembolic stroke [103]. In addition to pre-existing cardiac conditions, PPCM is associated with maternal stroke [98]. Rarely, maternal strokes due to endocarditis [104] and amniotic fluid embolism [105] have also been reported.

Hypercoagulability in pregnancy and postpartum period can promote both arterial and venous thrombosis. CVT is a common etiology of maternal stroke and occurs mainly during the postpartum period [75,101]. Propagation of thrombosis causes venous congestion, leading to venous infarct, hemorrhage, and increased intracranial pressure. Considering the five-times higher risk of deep vein thrombosis in pregnancy and the postpartum period [106], paradoxical embolism through a PFO can cause embolic stroke.

Adverse pregnancy outcomes and long-term risk of stroke

HDPs are well-known adverse pregnancy outcomes that increase long-term stroke risk [91,107,108]. In a meta-analysis of preeclampsia and future stroke, preeclampsia was associated with a ≈2-fold increased stroke risk [108]. A recent Taiwanese nationwide study with an overall follow-up period of 17 years investigated future stroke risk by stratification according to follow-up time and HDP subtype [91]. Women with HDPs had an adjusted HR (95% CI) of 1.71 (1.46-2.00) for stroke: 1.60 (1.35-1.89) and 2.98 (2.13-4.18) for ischemic and hemorrhagic stroke, respectively. Although the risks of both ischemic and hemorrhagic stroke persisted for up to the overall follow-up period, their risk time trends were different. The risk of ischemic stroke peaked around one to three years after childbirth with an HR of 2.14 (95% CI, 1.36-3.38), while that of hemorrhagic stroke increased after five years and kept increasing with time with an HR of 4.64 (95% CI, 2.47-8.73) after 10-15 years of childbirth. Regarding the HDP subtype, stroke risks were higher in women with HDP with preeclampsia than in women with HDP without preeclampsia. In detail, among the four HDP subtypes, chronic HTN with superimposed preeclampsia had the highest stroke risk followed by preeclampsia-eclampsia, gestational HTN, and chronic HTN with HRs (95% CI) of 3.86 (1.91-7.82), 2.00 (1.63-2.45), 1.68 (1.13-2.52), and 1.27 (0.97-1.68), respectively.

In a recent systematic review, other adverse pregnancy outcomes including gestational diabetes (RR [95% CI], 1.21 [1.05-1.40]) and preterm birth (HR [95% CI], 1.71 [1.53-1.91]) were associated with long-term stroke risk [109]. A recent Swedish national cohort of >2 million women found that preterm delivery was associated with higher future risks of both hemorrhagic and ischemic stroke up to at least 40 years even after adjusting for established risk factors with cosibling factors to account for shared genetic and environmental factors within families [110].

Exogenous estrogen

Use of oral contraceptive pills (OCPs) is associated with an increased risk of stroke [111-113]. In previous meta-analyses, women with current OCP use were at a ≈2.5-fold increased risk of ischemic stroke [111] and a ≈1.4-fold increased risk of hemorrhagic stroke [112]. The risk of stroke increases as the estrogen dose increases [111,113], but the progestin-only pill is not associated with increased risk of ischemic stroke [111,114]. The stroke risk in women with current OCP use is further increased by additional risk factors such as migraine, HTN, and current smoking [111,112]. According to a recent study, the stroke risk in women with OCP use was particularly high during the first year of OCP use, possibly due to immediate changes in hemostatic balance [115].

Oral menopausal hormone replacement therapy (HRT) also increases the risk of ischemic stroke [116,117]. In the two Women’s Health Initiative hormone therapy trials, the stroke risk was increased with both estrogen alone and estrogen plus progestin therapies and the risk was not evident for hemorrhagic stroke but was for ischemic stroke [117]. However, in a recent study, HRT was also associated with an increased event rate of SAH [115]. In this study, similarly with the result of OCP use, the stroke risk was especially high during the first year of HRT use (HR [95% CI], 2.12 [1.66-2.70]) and remained increased during remaining years of use (HR [95% CI], 1.18 [1.05-1.31]). Regarding the initiation of HRT, the “timing hypothesis” has been suggested that age and time since menopause influence the relationship between HRT and CVD [118]. Starting HRT might be more harmful when started more than 10 years after the onset of menopause or in women older than 60 years of age [119]. Observational studies suggest that the use of transdermal therapy containing low doses of estrogen has a lower stroke risk than oral HRT [119,120].

Lifetime endogenous estrogen exposure

The reproductive lifespan (defined as the time from menarche to menopause), which reflects endogenous estrogen exposure, is closely related to stroke risk [121]. In a large pooled analysis, women with a reproductive life span less than 30 years had a 75% higher risk of stroke than those with a reproductive life span of 36-38 years [121]. Compared with women with menarche at age 13 years, those with early menarche (≤10 years) and late menarche (≥16 years) had 27% and 25% increased risk of stroke, respectively. Compared with women aged 50-51 years at menopause, those with premature menopause (<40 years) and early menopause (40-44 years) had 98% and 49% higher risk of stroke, respectively [121]. In addition to natural menopause, surgical menopause by oophorectomy (with or without hysterectomy) is also associated with a higher risk of stroke [122,123]. Conflicting results have been reported regarding hysterectomy. In a previous meta-analysis, hysterectomy appeared to reduce the risk of stroke [122], but there are also contradictory results [123]. In a recent prospective study of almost 300,000 Chinese women, women who underwent hysterectomy alone and hysterectomy with bilateral oophorectomy had an ≈6% and ≈20% higher ischemic stroke risk, respectively, than those who did not undergo surgery, and these RRs were more extreme for those who were younger at the time of surgery [123].

Stroke outcomes (Figure 3)

Regarding stroke mortality, contradictory results have been shown depending on adjustments for confounders [4,124]. In the INSTRUCT (International Stroke Outcomes Study), a meta-analysis of individual participant data from 13 population-based incidence studies, the crude mortality rate ratio (MRR) was higher for women than men at 1 year (MRR [95% CI], 1.35 [1.24-1.47]) and 5 years (MRR [95% CI], 1.24 [1.12-1.38]) [124]. However, these results were reversed after adjusting for confounders including age, pre-stroke functional limitations, stroke severity, and history of AF (1-year MRR [95% CI], 0.81 [0.72-0.92] and 5-year MRR [95% CI], 0.76 [0.65-0.89]); this indicates that women’s higher mortality after stroke is attributable to these confounders (advanced age, greater stroke severity, worse pre-stroke status, and higher prevalence of AF) [124]. Similarly, in a recent prospective 25-year follow-up study from the UK, women had a 9% lower risk of death than men after full adjustment, while they had a 30% higher risk of death than men in an unadjusted analysis [4]. In a pooled analysis of individual participant data from five acute stroke randomized controls trials, after multivariable adjustments, women with ischemic stroke had higher survival rates at 3-6 months than men; however, this higher survival rate in women was not significant for ICH [125].

Women have poorer functional recovery and lower quality of life (QOL) than men after stroke. This finding has been consistently reported in many studies even after adjusting for several confounders [4,10,125-128]. Advanced age, more severe strokes, poorer pre-stroke function, more comorbidities, less social support, and a higher likelihood of being a widow are factors considered to contribute to a less favorable outcome in women; however, the causes have yet to be fully elucidated because adjustment for these factors does not adequately explain the sex differences in functional recovery and QOL after stroke [4,10,125-128].

Post-stroke depression (PSD) is more common in women than in men [126,129]. A previous systematic review suggested that the prevalence of PSD is 78% higher among women than among men [129]. In a more recent systematic review, women showed a higher likelihood of PSD (OR range, 1.27-3.15 and HR, 3.52) or higher mean PSD symptoms in an unadjusted analysis [126]. Even after multivariable adjustment for age, stroke severity, and activity limitations, women were still more likely to have a significantly higher prevalence, incidence, or symptoms of depression than men [126]. In addition to depression, women appear to have worse outcome than men in anxiety [4].

Regarding post-stroke cognitive impairment, previous studies have shown conflicting results [126]. In a recent population-based study examining sex differences in cognitive outcomes at 90 days after stroke among first-ever stroke patients, women had significantly lower levels of cognitive function and a higher unadjusted prevalence of dementia than men (35.6% vs. 27.6%) [130]. The differences were fully attenuated after adjustment for covariates, indicating that the major contributing factors to the worse post-stroke cognitive outcomes in women were a higher prevalence of being widowed, older age at stroke onset, worse pre-stroke functional and cognitive status, and lower educational attainment. Another recent cohort study of community-dwelling adults in the US found that women experience more post-stroke cognitive deficits even after controlling for pre-stroke cognitive measures, particularly during the early post-stroke period [131].

Conclusion

Women face a disproportionate burden of stroke. Women are more likely to have a stroke in their lifetime and have poorer post-stroke outcomes. There are a number of sex differences in the impact of conventional risk factors on stroke, which indicates that the optimal management of stroke risk factors may differ between men and women. For better understanding of this, the problem of underrepresentation of women in clinical trials [132] must be improved and well-designed studies powered to detect sex-based differences are required. Further research into the underlying mechanisms responsible for these sex differences is also warranted. Women have unique stroke risk factors such as pregnancy, endogenous hormone levels, and exogenous hormone therapy. These women-specific risk factors should be considered in optimal risk assessment and tailored preventive strategies for women.

Notes

Disclosure

The authors have no financial conflicts of interest

Figure 1.

Stroke risk factors in women. The numbers are references supporting each finding.

Figure 2.

Pathophysiology and possible etiologies of maternal stroke.

Figure 3.

Stroke outcomes in women. The numbers are references supporting each finding.

Table 1.

Comparison of stroke incidence in young women vs. men in studies published between 2019 and 2022

Study	Results			Stroke incidence in young adults
Greater Cincinnati/Northern Kentucky Stroke Study [6]	Women-men stroke incidence rate ratio (95% CI)			Women ≈ Men (20-44 years)
		20-44 years
			: 0.82 (0.54-1.10) (in 2015)
			: 1.11 (0.71-1.51) (in 2010)
			: 1.30 (0.87-1.74) (in 2005)
			: 1.12 (0.70-1.54) (in 1999)
			: 1.32 (0.75-1.89) (in 1993/1994)
Canadian cohort study [7]	Hazard ratio of stroke in women compared to men (95% CI)			Women > Men (18-29 years)
		18-29 years: 1.26 (1.10-1.45)		Women ≈ Men (30-39 years)
		30-39 years: 1.00 (0.94-1.06)
US health insurance database study [8]	Men-women stroke incidence rate ratio (95% CI)			Women > Men (25-44 years)
		25-34 years: 0.70 (0.57-0.86)
		35-44 years: 0.87 (0.78-0.98)
Dutch nationwide cohort study [9]	Women-men stroke incidence rate ratio (95% CI)			Women > Men (18-44 years)
		18-24 years: 1.93 (1.62-2.31)
		25-29 years: 1.91 (1.61-2.26)
		30-34 years: 1.46 (1.29-1.63)
		35-39 years: 1.25 (1.15-1.36)
		40-44 years: 1.14 (1.07-1.22)

CI, confidence interval.

References

1. Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, et al. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2021;20:795-820.

2. Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, et al. World Stroke Organization (WSO): global stroke fact sheet 2022. Int J Stroke 2022;17:18-29.

3. Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Au R, Kannel WB, et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke 2006;37:345-350.

4. Xu M, Amarilla Vallejo A, Cantalapiedra Calvete C, Rudd A, Wolfe C, O’Connell MDL, et al. Stroke outcomes in women: a population-based cohort study. Stroke 2022;53:3072-3081.

5. Appelros P, Stegmayr B, Terént A. Sex differences in stroke epidemiology: a systematic review. Stroke 2009;40:1082-1090.

6. Madsen TE, Khoury JC, Leppert M, Alwell K, Moomaw CJ, Sucharew H, et al. Temporal trends in stroke incidence over time by sex and age in the GCNKSS. Stroke 2020;51:1070-1076.

7. Vyas MV, Silver FL, Austin PC, Yu AYX, Pequeno P, Fang J, et al. Stroke incidence by sex across the lifespan. Stroke 2021;52:447-451.

8. Leppert MH, Ho PM, Burke J, Madsen TE, Kleindorfer D, Sillau S, et al. Young women had more strokes than young men in a large, United States claims sample. Stroke 2020;51:3352-3355.

9. Ekker MS, Verhoeven JI, Vaartjes I, van Nieuwenhuizen KM, Klijn CJM, de Leeuw FE. Stroke incidence in young adults according to age, subtype, sex, and time trends. Neurology 2019;92:e2444-e2454.

10. Petrea RE, Beiser AS, Seshadri S, Kelly-Hayes M, Kase CS, Wolf PA. Gender differences in stroke incidence and poststroke disability in the Framingham Heart Study. Stroke 2009;40:1032-1037.

11. Gardener H, Sacco RL, Rundek T, Battistella V, Cheung YK, Elkind MSV. Race and ethnic disparities in stroke incidence in the Northern Manhattan Study. Stroke 2020;51:1064-1069.

12. Arnao V, Acciarresi M, Cittadini E, Caso V. Stroke incidence, prevalence and mortality in women worldwide. Int J Stroke 2016;11:287-301.

13. Koton S, Sang Y, Schneider ALC, Rosamond WD, Gottesman RF, Coresh J. Trends in stroke incidence rates in older US adults: an update from the Atherosclerosis Risk in Communities (ARIC) cohort study. JAMA Neurol 2020;77:109-113.

14. GBD 2016 Lifetime Risk of Stroke Collaborators. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med 2018;379:2429-2437.

15. Cras TY, Bos D, Ikram MA, Vergouwen MDI, Dippel DWJ, Voortman T, et al. Determinants of the presence and size of intracranial aneurysms in the general population: the Rotterdam study. Stroke 2020;51:2103-2110.

16. Fuentes AM, Stone McGuire L, Amin-Hanjani S. Sex differences in cerebral aneurysms and subarachnoid hemorrhage. Stroke 2022;53:624-633.

17. Rehman S, Sahle BW, Chandra RV, Dwyer M, Thrift AG, Callisaya M, et al. Sex differences in risk factors for aneurysmal subarachnoid haemorrhage: systematic review and meta-analysis. J Neurol Sci 2019;406:116446.

18. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021;398:957-980.

19. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 2016;134:441-450.

20. Beaney T, Burrell LM, Castillo RR, Charchar FJ, Cro S, Damasceno A, et al. May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. Eur Heart J 2019;40:2006-2017.

21. Redfern A, Peters SAE, Luo R, Cheng Y, Li C, Wang J, et al. Sex differences in the awareness, treatment, and control of hypertension in China: a systematic review with meta-analyses. Hypertens Res 2019;42:273-283.

22. Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015-2016. NCHS Data Brief 2017;289:1-8.

23. Zhang Y, Moran AE. Trends in the prevalence, awareness, treatment, and control of hypertension among young adults in the United States, 1999 to 2014. Hypertension 2017;70:736-742.

24. Sarganas G, Neuhauser HK. The persisting gender gap in hypertension management and control in Germany: 1998 and 2008-2011. Hypertens Res 2016;39:457-466.

25. Choi HM, Kim HC, Kang DR. Sex differences in hypertension prevalence and control: analysis of the 2010-2014 Korea National Health and Nutrition Examination Survey. PLoS One 2017;12:e0178334.

26. Zhou B, Danaei G, Stevens GA, Bixby H, Taddei C, CarrilloLarco RM, et al. Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet 2019;394:639-651.

27. O’Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016;388:761-775.

28. Peters SA, Huxley RR, Woodward M. Comparison of the sex-specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals. Stroke 2013;44:2394-2401.

29. Peters SAE, Carcel C, Millett ERC, Woodward M. Sex differences in the association between major risk factors and the risk of stroke in the UK Biobank cohort study. Neurology 2020;95:e2715-e2726.

30. Madsen TE, Howard G, Kleindorfer DO, Furie KL, Oparil S, Manson JE, et al. Sex differences in hypertension and stroke risk in the REGARDS study: a longitudinal cohort study. Hypertension 2019;74:749-755.

31. Ji H, Niiranen TJ, Rader F, Henglin M, Kim A, Ebinger JE, et al. Sex differences in blood pressure associations with cardiovascular outcomes. Circulation 2021;143:761-763.

32. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019;157:107843.

33. Peters SAE, Muntner P, Woodward M. Sex differences in the prevalence of, and trends in, cardiovascular risk factors, treatment, and control in the United States, 2001 to 2016. Circulation 2019;139:1025-1035.

34. Franzini L, Ardigò D, Cavalot F, Miccoli R, Rivellese AA, Trovati M, et al. Women show worse control of type 2 diabetes and cardiovascular disease risk factors than men: results from the MIND.IT Study Group of the Italian Society of Diabetology. Nutr Metab Cardiovasc Dis 2013;23:235-241.

35. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-2222.

36. Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley TH Jr, Folsom AR. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study. Stroke 2006;37:2493-2498.

37. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 2014;383:1973-1980.

38. Gnatiuc L, Herrington WG, Halsey J, Tuomilehto J, Fang X, Kim HC, et al. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies. Lancet Diabetes Endocrinol 2018;6:538-546.

39. Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol 2016;13:321-332.

40. Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M, et al. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ 2016;352:h7013.

41. Nielsen PB, Skjøth F, Overvad TF, Larsen TB, Lip GYH. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA₂DS₂-VA score rather than CHA₂DS₂-VASc? Circulation 2018;137:832-840.

42. Thompson LE, Maddox TM, Lei L, Grunwald GK, Bradley SM, Peterson PN, et al. Sex differences in the use of oral anticoagulants for atrial fibrillation: a report from the national cardiovascular data registry (NCDR®) PINNACLE registry. J Am Heart Assoc 2017;6:e005801.

43. Yong CM, Tremmel JA, Lansberg MG, Fan J, Askari M, Turakhia MP. Sex differences in oral anticoagulation and outcomes of stroke and intracranial bleeding in newly diagnosed atrial fibrillation. J Am Heart Assoc 2020;9:e015689.

44. Avgil Tsadok M, Gagnon J, Joza J, Behlouli H, Verma A, Essebag V, et al. Temporal trends and sex differences in pulmonary vein isolation for patients with atrial fibrillation. Heart Rhythm 2015;12:1979-1986.

45. Cheng X, Hu Q, Gao L, Liu J, Qin S, Zhang D. Sex-related differences in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace 2019;21:1509-1518.

46. Darden D, Duong T, Du C, Munir MB, Han FT, Reeves R, et al. Sex differences in procedural outcomes among patients undergoing left atrial appendage occlusion: insights from the NCDR LAAO registry. JAMA Cardiol 2021;6:1275-1284.

47. Abusnina W, Latif A, Al-Abdouh A, Mostafa MR, Radaideh Q, Alshebani Y, et al. Sex differences in the clinical outcomes after left atrial appendage closure: a systematic review and meta-analysis. Cardiovasc Revasc Med 2022;41:29-34.

48. Huang Y, Gao L, Xie X, Tan SC. Epidemiology of dyslipidemia in Chinese adults: meta-analysis of prevalence, awareness, treatment, and control. Popul Health Metr 2014;12:28.

49. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004;63:1868-1875.

50. Yaghi S, Elkind MS. Lipids and cerebrovascular disease: research and practice. Stroke 2015;46:3322-3328.

51. Gu X, Li Y, Chen S, Yang X, Liu F, Li Y, et al. Association of lipids with ischemic and hemorrhagic stroke: a prospective cohort study among 267 500 Chinese. Stroke 2019;50:3376-3384.

52. Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM. Lipid levels and the risk of ischemic stroke in women. Neurology 2007;68:556-562.

53. Peters SA, Singhateh Y, Mackay D, Huxley RR, Woodward M. Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: a systematic review and meta-analysis. Atherosclerosis 2016;248:123-131.

54. Hong KS, Lee JS. Statins in acute ischemic stroke: a systematic review. J Stroke 2015;17:282-301.

55. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397-1405.

56. Zhao M, Woodward M, Vaartjes I, Millett ERC, Klipstein-Grobusch K, Hyun K, et al. Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta-analysis. J Am Heart Assoc 2020;9:e014742.

57. Nanna MG, Wang TY, Xiang Q, Goldberg AC, Robinson JG, Roger VL, et al. Sex differences in the use of statins in community practice: patient and provider assessment of lipid management registry. Circ Cardiovasc Qual Outcomes 2019;12:e005562.

58. Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, AlRaddadi RM, et al. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17:954-976.

59. Lee MJ, Lee C, Chung CS. The migraine-stroke connection. J Stroke 2016;18:146-156.

60. Mahmoud AN, Mentias A, Elgendy AY, Qazi A, Barakat AF, Saad M, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open 2018;8:e020498.

61. Sacco S, Ornello R, Ripa P, Pistoia F, Carolei A. Migraine and hemorrhagic stroke: a meta-analysis. Stroke 2013;44:3032-3038.

62. Gaist D, González-Pérez A, Ashina M, Rodríguez LA. Migraine and risk of hemorrhagic stroke: a study based on data from general practice. J Headache Pain 2014;15:74.

63. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009;339:b3914.

64. Garawi F, Devries K, Thorogood N, Uauy R. Global differences between women and men in the prevalence of obesity: is there an association with gender inequality? Eur J Clin Nutr 2014;68:1101-1106.

65. Fryar CD, Carroll MD, Afful J. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960-1962 through 2017-2018 Hyattsville, MD: NCHS Health E-Stats; 2020. p. 1-7.

66. Yatsuya H, Folsom AR, Yamagishi K, North KE, Brancati FL, Stevens J. Race- and sex-specific associations of obesity measures with ischemic stroke incidence in the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2010;41:417-425.

67. Kroll ME, Green J, Beral V, Sudlow CL, Brown A, Kirichek O, et al. Adiposity and ischemic and hemorrhagic stroke: prospective study in women and meta-analysis. Neurology 2016;87:1473-1481.

68. Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 2014;311:183-192.

69. Pan B, Jin X, Jun L, Qiu S, Zheng Q, Pan M. The relationship between smoking and stroke: a meta-analysis. Medicine (Baltimore) 2019;98:e14872.

70. Peters SA, Huxley RR, Woodward M. Smoking as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 81 cohorts, including 3,980,359 individuals and 42,401 strokes. Stroke 2013;44:2821-2828.

71. Swartz RH, Cayley ML, Foley N, Ladhani NNN, Leffert L, Bushnell C, et al. The incidence of pregnancy-related stroke: a systematic review and meta-analysis. Int J Stroke 2017;12:687-697.

72. Elgendy IY, Gad MM, Mahmoud AN, Keeley EC, Pepine CJ. Acute stroke during pregnancy and puerperium. J Am Coll Cardiol 2020;75:180-190.

73. Karjalainen L, Tikkanen M, Rantanen K, Aarnio K, Korhonen A, Saaros A, et al. Stroke in pregnancy and puerperium: validated incidence trends with risk factor analysis in Finland 1987-2016. Neurology 2021;96:e2564-e2575.

74. Ban L, Sprigg N, Abdul Sultan A, Nelson-Piercy C, Bath PM, Ludvigsson JF, et al. Incidence of first stroke in pregnant and nonpregnant women of childbearing age: a population-based cohort study from England. J Am Heart Assoc 2017;6:e004601.

75. Silvis SM, Lindgren E, Hiltunen S, Devasagayam S, Scheres LJ, Jood K, et al. Postpartum period is a risk factor for cerebral venous thrombosis. Stroke 2019;50:501-503.

76. Sanghavi M, Rutherford JD. Cardiovascular physiology of pregnancy. Circulation 2014;130:1003-1008.

77. Stergiopoulos K, Shiang E, Bench T. Pregnancy in patients with pre-existing cardiomyopathies. J Am Coll Cardiol 2011;58:337-350.

78. Porras JL, Yang W, Philadelphia E, Law J, Garzon-Muvdi T, Caplan JM, et al. Hemorrhage risk of brain arteriovenous malformations during pregnancy and puerperium in a North American cohort. Stroke 2017;48:1507-1513.

79. Beighley A, Glynn R, Scullen T, Mathkour M, Werner C, Berry JF, et al. Aneurysmal subarachnoid hemorrhage during pregnancy: a comprehensive and systematic review of the literature. Neurosurg Rev 2021;44:2511-2522.

80. Salehi Omran S, Parikh NS, Poisson S, Armstrong J, Merkler AE, Prabhu M, et al. Association between pregnancy and cervical artery dissection. Ann Neurol 2020;88:596-602.

81. Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004;114:409-414.

82. Thornton P, Douglas J. Coagulation in pregnancy. Best Pract Res Clin Obstet Gynaecol 2010;24:339-352.

83. James AH, Bushnell CD, Jamison MG, Myers ER. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 2005;106:509-516.

84. Mor G, Cardenas I, Abrahams V, Guller S. Inflammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci 2011;1221:80-87.

85. Boeldt DS, Bird IM. Vascular adaptation in pregnancy and endothelial dysfunction in preeclampsia. J Endocrinol 2017;232:R27-R44.

86. Romero R, Gotsch F, Pineles B, Kusanovic JP. Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. Nutr Rev 2007;65(12 Pt 2):S194-S202.

87. Kelly PJ, Lemmens R, Tsivgoulis G. Inflammation and stroke risk: a new target for prevention. Stroke 2021;52:2697-2706.

88. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018;72:24-43.

89. Ying W, Catov JM, Ouyang P. Hypertensive disorders of pregnancy and future maternal cardiovascular risk. J Am Heart Assoc 2018;7:e009382.

90. Leffert LR, Clancy CR, Bateman BT, Bryant AS, Kuklina EV. Hypertensive disorders and pregnancy-related stroke: frequency, trends, risk factors, and outcomes. Obstet Gynecol 2015;125:124-131.

91. Hung SK, Lee MS, Lin HY, Chen LC, Chuang CJ, Chew CH, et al. Impact of hypertensive disorders of pregnancy on the risk of stroke stratified by subtypes and follow-up time. Stroke 2022;53:338-344.

92. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta 2009;30(Suppl A):S32-S37.

93. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol 2010;5:173-192.

94. McDermott M, Miller EC, Rundek T, Hurn PD, Bushnell CD. Preeclampsia: association with posterior reversible encephalopathy syndrome and stroke. Stroke 2018;49:524-530.

95. Bello N, Rendon ISH, Arany Z. The relationship between preeclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol 2013;62:1715-1723.

96. Hoes MF, Arany Z, Bauersachs J, Hilfiker-Kleiner D, Petrie MC, Sliwa K, et al. Pathophysiology and risk factors of peripartum cardiomyopathy. Nat Rev Cardiol 2022;19:555-565.

97. Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation 2016;133:1397-1409.

98. Sliwa K, Petrie MC, van der Meer P, Mebazaa A, Hilfiker-Kleiner D, Jackson AM, et al. Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J 2020;41:3787-3797.

99. Liu S, Chan WS, Ray JG, Kramer MS, Joseph KS; Canadian Perinatal Surveillance System (Public Health Agency of Canada). Stroke and cerebrovascular disease in pregnancy: incidence, temporal trends, and risk factors. Stroke 2019;50:13-20.

100. Meeks JR, Bambhroliya AB, Alex KM, Sheth SA, Savitz SI, Miller EC, et al. Association of primary intracerebral hemorrhage with pregnancy and the postpartum period. JAMA Netw Open 2020;3:e202769.

101. Miller EC, Yaghi S, Boehme AK, Willey JZ, Elkind MS, Marshall RS. Mechanisms and outcomes of stroke during pregnancy and the postpartum period: a cross-sectional study. Neurol Clin Pract 2016;6:29-39.

102. Maragkos GA, Ascanio LC, Chida K, Boone MD, Ogilvy CS, Thomas AJ, et al. Moyamoya disease in pregnancy: a systematic review. Acta Neurochir (Wien) 2018;160:1711-1719.

103. Uebing A, Steer PJ, Yentis SM, Gatzoulis MA. Pregnancy and congenital heart disease. BMJ 2006;332:401-406.

104. Connolly C, O’Donoghue K, Doran H, McCarthy FP. Infective endocarditis in pregnancy: case report and review of the literature. Obstet Med 2015;8:102-104.

105. Woo YS, Hong SC, Park SM, Cho KH. Ischemic stroke related to an amniotic fluid embolism during labor. J Clin Neurosci 2015;22:767-768.

106. Greer IA. Pregnancy complicated by venous thrombosis. N Engl J Med 2015;373:540-547.

107. de Havenon A, Delic A, Stulberg E, Sheibani N, Stoddard G, Hanson H, et al. Association of preeclampsia with incident stroke in later life among women in the Framingham Heart Study. JAMA Netw Open 2021;4:e215077.

108. Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2017;10:e003497.

109. Okoth K, Chandan JS, Marshall T, Thangaratinam S, Thomas GN, Nirantharakumar K, et al. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. BMJ 2020;371:m3502.

110. Crump C, Sundquist J, Sundquist K. Preterm delivery and long-term risk of stroke in women: a national cohort and cosibling study. Circulation 2021;143:2032-2044.

111. Xu Z, Li Y, Tang S, Huang X, Chen T. Current use of oral contraceptives and the risk of first-ever ischemic stroke: a meta-analysis of observational studies. Thromb Res 2015;136:52-60.

112. Xu Z, Yue Y, Bai J, Shen C, Yang J, Huang X, et al. Association between oral contraceptives and risk of hemorrhagic stroke: a meta-analysis of observational studies. Arch Gynecol Obstet 2018;297:1181-1191.

113. Li F, Zhu L, Zhang J, He H, Qin Y, Cheng Y, et al. Oral contraceptive use and increased risk of stroke: a dose-response meta-analysis of observational studies. Front Neurol 2019;10:993.

114. Chakhtoura Z, Canonico M, Gompel A, Thalabard JC, Scarabin PY, Plu-Bureau G. Progestogen-only contraceptives and the risk of stroke: a meta-analysis. Stroke 2009;40:1059-1062.

115. Johansson T, Fowler P, Ek WE, Skalkidou A, Karlsson T, Johansson Å. Oral contraceptives, hormone replacement therapy, and stroke risk. Stroke 2022;53:3107-3115.

116. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861-866.

117. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353-1368.

118. Nudy M, Chinchilli VM, Foy AJ. A systematic review and meta-regression analysis to examine the ‘timing hypothesis’ of hormone replacement therapy on mortality, coronary heart disease, and stroke. Int J Cardiol Heart Vasc 2019;22:123-131.

119. Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Med 2020;382:446-455.

120. Renoux C, Dell’aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519.

121. Mishra SR, Chung HF, Waller M, Dobson AJ, Greenwood DC, Cade JE, et al. Association between reproductive life span and incident nonfatal cardiovascular disease: a pooled analysis of individual patient data from 12 studies. JAMA Cardiol 2020;5:1410-1418.

122. Poorthuis MH, Algra AM, Algra A, Kappelle LJ, Klijn CJ. Female-and male-specific risk factors for stroke: a systematic review and meta-analysis. JAMA Neurol 2017;74:75-81.

123. Poorthuis MHF, Yao P, Chen Y, Guo Y, Shi L, Li L, et al. Risks of stroke and heart disease following hysterectomy and oophorectomy in Chinese premenopausal women. Stroke 2022;53:3064-3071.

124. Phan HT, Blizzard CL, Reeves MJ, Thrift AG, Cadilhac D, Sturm J, et al. Sex differences in long-term mortality after stroke in the INSTRUCT (INternational STRoke oUtComes sTudy): a meta-analysis of individual participant data. Circ Cardiovasc Qual Outcomes 2017;10:e003436.

125. Carcel C, Wang X, Sandset EC, Delcourt C, Arima H, Lindley R, et al. Sex differences in treatment and outcome after stroke: pooled analysis including 19,000 participants. Neurology 2019;93:e2170-e2180.

126. Gall S, Phan H, Madsen TE, Reeves M, Rist P, Jimenez M, et al. Focused update of sex differences in patient reported outcome measures after stroke. Stroke 2018;49:531-535.

127. Phan HT, Blizzard CL, Reeves MJ, Thrift AG, Cadilhac DA, Sturm J, et al. Sex differences in long-term quality of life among survivors after stroke in the INSTRUCT. Stroke 2019;50:2299-2306.

128. Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol 2008;7:915-926.

129. Poynter B, Shuman M, Diaz-Granados N, Kapral M, Grace SL, Stewart DE. Sex differences in the prevalence of post-stroke depression: a systematic review. Psychosomatics 2009;50:563-569.

130. Dong L, Briceno E, Morgenstern LB, Lisabeth LD. Poststroke cognitive outcomes: sex differences and contributing factors. J Am Heart Assoc 2020;9:e016683.

131. Bako AT, Potter T, Tannous J, Pan AP, Johnson C, Baig E, et al. Sex differences in post-stroke cognitive decline: a population-based longitudinal study of nationally representative data. PLoS One 2022;17:e0268249.

132. Strong B, Pudar J, Thrift AG, Howard VJ, Hussain M, Carcel C, et al. Sex disparities in enrollment in recent randomized clinical trials of acute stroke: a meta-analysis. JAMA Neurol 2021;78:666-677.

	Editorial Office Department of Neurology, Asan Medical Center,Ulsan University College of Medicine 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea Submission, status and progress, etc ⟫ E-mail: editor@j-stroke.org Website and system ⟫ E-mail: journal@m2community.co.kr Publishing company ⟫ E-mail: ka72sus@smileml.com
	Copyright © 2024 by Korean Stroke Society.